期刊文献+
共找到431篇文章
< 1 2 22 >
每页显示 20 50 100
Shenkang Ⅶ Recipe Attenuates Unilateral Ureteral Obstruction-induced Renal Fibrosis via TGF-β/Smad, NF-κB and SHH Signaling Pathway 被引量:4
1
作者 Shan-shan ZHOU Zhong-zhu AI +3 位作者 Wei-nan LI Liang LI Xiao-yun ZHU Yuan-ming BA 《Current Medical Science》 SCIE CAS 2020年第5期917-930,共14页
This study aimed to explore the protective effects of the traditional Chinese Medicine formula Shenkang Ⅶ recipe(SK-7)on renal fibrosis and the mechanisms.Renal fibrosis was induced by unilateral ureteral obstruction... This study aimed to explore the protective effects of the traditional Chinese Medicine formula Shenkang Ⅶ recipe(SK-7)on renal fibrosis and the mechanisms.Renal fibrosis was induced by unilateral ureteral obstruction(UUO)in rats.The rats were then divided into 5 groups:control group(Sham operation),UUO model group,UUO model plus low to high doses of SK-7(0.5,1.0,or 2.0 g/kg/day,for 14 days)groups.The animals were sacrificed on the 7th or 14th day.K idney tissues were collected for histopathological exarminations(hematoxylin and cosin and Masson's trichrome staining).Immunohistochemistry was used to detect the expression of collagen type II(Col II),fibronectin(FN),α-smooth muscle actin(a-SMA),TIMP metallopeptidase inhibitor 2(TIMP2),matrix metallopeptidase 2(MMP2),tumor necrosis factor-α(TNF-α),interleukin-1β(IL-1β)and monocyte chemotactic protein-1(MCP-1).The TGF-β1/Smad,NF-κB and Sonic hedgehog signaling proteins were detected by Western blotting.Our results showed that SK-7 prevented UUO-induced renal injury and accumulation of collagen fibrils.Renal fbrosis biomarkers Col Ⅲ,FN,α-SMA and TMP2 were increased in the rats after UUO and decreased by SK-7,while MMP2 was upregulated after treatment.SK-7 also suppressed the levels of TNF-α,IL-1βand MCP-1 in UUO rats.In addition,SK-7 inhibited activation of the TGF-B/Smad,NF-κB and sonic hedgehog signaling(SHH)pathways.Taken together,these findings suggest that SK-7 may regulate the synthesis and degradation of extracellular matrix,reduce inflammation and suppress the proliferation of fibroblasts,by blocking the TGF-β1/Smad,NF-κB and SHH signaling pathways to exert its anti-renal fbrosis effect in UUO rats. 展开更多
关键词 shenkangⅦrecipe(SK-7) chronic kidney disease renal fibrosis signaling pathway
下载PDF
Effect of Shenkang granule combined with Atorvastatin on renal function, urinary protein and coagulation function in patients with chronic nephritis
2
作者 Yan-Yu Yang Nan Li +1 位作者 Yong-Gang Zhang Jing Zhang 《Journal of Hainan Medical University》 2018年第21期49-52,共4页
Objective: To investigate the effect of Shenkang granule combined with Atorvastatin on renal function, urinary protein and coagulation function in patients with chronic nephritis. Methods:A total of 100 patients with ... Objective: To investigate the effect of Shenkang granule combined with Atorvastatin on renal function, urinary protein and coagulation function in patients with chronic nephritis. Methods:A total of 100 patients with chronic nephritis who were treated in our hospital between May 2016 to May 2017 were randomly divided into control group and observation group, 50 cases in each group. Patients in the control group were treated with Atorvastatin, while patients in the observation group were treated with Shenkang granule on the basis of the treatment in the control group. The changes of renal function, coagulation function and inflammatory factors were detected and compared between the patients in the two groups before and after treatment. Result: After treatment, the levels of Cr, BUN and 24hUpro in serum of patients in the two groups were significantly decreased, and the levels of ALB were significantly increased, and the changes of the above factors of patients in the observation group were more obvious. After treatment, the levels of PT, APTT and TT of patients in the two groups were significantly increased, and the levels of FIB were significantly decreased, and the changes of the above indexes of patients in the observation group were more obvious. After treatment, the levels of hs-CRP and TNF-α in serum of patients in the two groups were significantly decreased, and the decrease trend of inflammatory factors of patients in the observation group was more obvious. Conclusion: Shenkang granule combined with Atorvastatin has a good effect on treatment of chronic nephritis. It can significantly improve renal function and coagulation function, alleviate inflammation, and has a certain protective effect on kidney of patients. 展开更多
关键词 shenkang GRANULE ATORVASTATIN Chronic NEPHRITIS Renal FUNCTION COAGULATION FUNCTION Inflammatory reaction
下载PDF
Effects of Shenkang Injection Combined with Hemodialysis on Dialysis Rate and Nutriture in Patients with Chronic Renal Failure
3
作者 Zhang Huifang Wu Rongying 《World Journal of Integrated Traditional and Western Medicine》 2019年第4期21-26,共6页
OBJECTIVE: To explore the effects of Shenkang Injection combined with hemodialysis on dialysis rate and nutriture in patients with chronic renal failure (CRF).METHODS: A total of 110 CRF patients admitted in the hospi... OBJECTIVE: To explore the effects of Shenkang Injection combined with hemodialysis on dialysis rate and nutriture in patients with chronic renal failure (CRF).METHODS: A total of 110 CRF patients admitted in the hospital from January 2016 to January 2018 were randomly divided into 2 groups.The control group was treated with hemodialysis while the observation group was additionally treated with Shenkang Injection on the treatment basis of the control group.They were treated for 4 weeks and reexamined 1 d after the treatment.Renal function,nutriture,dialysis adequacy,oxidative stress level and inflammatory factor level in the 2 groups were determined before and after the treatment,and traditional Chinese medicine (TCM) syndrome score,dialysis rate within 1 week and incidence of adverse reactions during the treatment were counted before and after the treatment.RESULTS: After the treatment,the levels of serum creatinine (Scr) and urea nitrogen (BUN) in the observation group were lower than those in the control group,and the endogenous creatinine clearance rate (Ccr) was higher than that in the control group (P < 0.05).After the treatment,the nutriture in the observation group was better than that in the control group (P < 0.05).After the treatment,the dialysis rate and time average concentration of urea (TACurea) in the observation group were lower than those in the control group,while the overall urea clearance rate (Kt/V) and protein catabolic rate (PCR) were higher than those in the control group (P < 0.05).After the treatment,the TCM syndrome scores in the observation group was lower than that in the control group (P < 0.05) and the level of serum malondialdehyde (MDA) in the observation group was lower than that in the control,while the level of superoxide dismutase (SOD) and total antioxidant capacity (T-AOC) in the observation group were higher than those in the control group (P < 0.05).After the treatment,the levels of inflammatory factors in the observation group were lower than those in the control group (P < 0.05).No serious adverse reactions occurred in the 2 groups.CONCLUSION: Shenkang Injection combined with hemodialysis for the treatment of CRF can effectively improve clinical symptoms and nutriture,and reduce the dialysis rate. 展开更多
关键词 shenkang Injection CHRONIC RENAL failure DIALYSIS RATE Nutriture
下载PDF
Meta-analysis of the efficacy and safety of Shenkang injection combined with Western medicine in the treatment of chronic glomerulonephritis
4
作者 Yang Liu Yue Ji +8 位作者 Zi-Xuan Zhao Lu-Xuan Guo Jin Lin Rong-Xin Zheng Guan-Ran Wang Jin-Hua Si Xin-Yuan Zhang Na Hao Hong-Tao Yang 《Clinical Research Communications》 2022年第4期6-16,共11页
Objective:The purpose of the research was to systematically evaluate the clinical efficacy and safety of Shenkang injection combined with Western medicine in treating chronic glomerulonephritis.Methods:Randomized cont... Objective:The purpose of the research was to systematically evaluate the clinical efficacy and safety of Shenkang injection combined with Western medicine in treating chronic glomerulonephritis.Methods:Randomized controlled trials of Shenkang Injection combined with Western medicine in treating CGN were obtained from 8 Science databases including China National Knowledge Infrastructure(CNKI),China Biomedical Database(SinMed),Weipu Database(VIP),Wanfang Database(Wanfang),PubMed,The Cochrane Library,Embase,Web of Science from establishment to June 2022.Two researchers screened literature and extracted useful data according to inclusion and exclusion criteria,and used RevMan 5.3 and STATA SE 14.0 software to perform meta-analysis.Results:1,214 patients were included in 15 studies,with 607 in treatment group and 607 in control group.The results of meta-analysis showed that the treatment group could improve the clinical effective rate[RR=1.33,95%CI(1.25,1.40),P<0.00001],reduce serum creatinine[MD=-31.28,95%CI(-42.90,-19.66),P<0.00001],blood urea nitrogen[MD=-2.26,95%CI(-3.08,-1.44),P<0.00001],24-hour urine protein quantification[MD=-0.37,95%CI(-0.49,-0.25),P<0.00001],tumor necrosis factor-α[MD=-7.93,95%CI(-10.56,-5.30),P<0.00001],systolic blood pressure[MD=-10.81,95%CI(-13.66,-7.96),P<0.00001]and diastolic blood pressure[MD=-7.36,95%CI(-9.34,-5.38),P<0.00001].Conclusion:Shenkang injection combined with Western medicine can enhance the clinical effective rate of CGN and reduce the levels of serum creatinine,blood urea nitrogen,24-hour urine protein quantification,tumor necrosis factor-α,systolic blood and diastolic blood pressure.However,due to the low quality of literature,the conclusion still needs to be supported by more multi-center,large-sample studies with rigorous design and standardized implementation. 展开更多
关键词 shenkang injection chronic glomerulonephritis curative effect randomized controlled trials META-ANALYSIS
下载PDF
硫辛酸联合肾康注射液治疗早期糖尿病肾脏病的临床疗效
5
作者 梁江燕 廖伟玲 +1 位作者 李锋 张林潮 《糖尿病新世界》 2024年第14期1-4,共4页
目的探讨硫辛酸联合肾康注射液治疗早期糖尿病肾脏病(diabetic kidney disease,DKD)的疗效及对炎症的影响。方法选取2020年6月—2021年12月柳州市柳铁中心医院收治的97例DKD患者为研究对象,以治疗方法的不同将患者分为A组(34例,硫辛酸... 目的探讨硫辛酸联合肾康注射液治疗早期糖尿病肾脏病(diabetic kidney disease,DKD)的疗效及对炎症的影响。方法选取2020年6月—2021年12月柳州市柳铁中心医院收治的97例DKD患者为研究对象,以治疗方法的不同将患者分为A组(34例,硫辛酸、肾康联合厄贝沙坦治疗)、B组(33例,肾康联合厄贝沙坦治疗)、对照C组(30例,厄贝沙坦治疗),均治疗2周。比较3组患者临床疗效、尿白蛋白/尿肌酐(urinary albu⁃min/creatinine,UACR)、血肌酐(serum creatinine,Scr)、尿素氮(blood urea nitrogen,BUN)、肾小球滤过率估算值(estimated glomerular filtration rate,eGFR)、超敏C反应蛋白(high-sensitivity C-reactive protein,hs-CRP)、空腹血糖、不良反应发生率。结果A、B组治疗总有效率高于C组,且A组治疗总有效率高于B组,差异有统计学意义(P均<0.05)。治疗后,与C组相比,A、B组UACR水平均降低,且A组低于B组,差异有统计学意义(P均<0.05)。治疗后,与B组和C组比较,A组Scr和hs-CRP均显著降低,eGFR显著增加差异有统计学意义(P均<0.05)。3组不良反应发生率比较,差异无统计学意义(P>0.05)。结论硫辛酸联合肾康、厄贝沙坦治疗早期DKD能抑制炎症因子的释放,从而起到延缓DKD、保护肾脏的作用。 展开更多
关键词 糖尿病肾脏病 硫辛酸 肾康注射液 厄贝沙坦
下载PDF
基于生物信息学和体外实验验证的肾康注射液治疗肾纤维化作用机制研究
6
作者 孟高全 张明亮 +9 位作者 陈小菲 王晓艳 李伟霞 张岱 蒋露 李明格 张小帅 孟伟亭 韩冰 唐进法 《中国药理学通报》 CAS CSCD 北大核心 2024年第10期1953-1962,共10页
目的 利用生物信息学及体外实验探讨肾康注射液(Shenkang injection, SKI)治疗肾纤维化(renal fibrosis, RF)的作用机制与物质基础。方法 利用GEO数据库筛选RF差异表达基因,借助CMAP数据库,基于基因表达谱相似性原理,重定位出具有调控R... 目的 利用生物信息学及体外实验探讨肾康注射液(Shenkang injection, SKI)治疗肾纤维化(renal fibrosis, RF)的作用机制与物质基础。方法 利用GEO数据库筛选RF差异表达基因,借助CMAP数据库,基于基因表达谱相似性原理,重定位出具有调控RF作用的药物,然后通过分子指纹相似性分析筛选出SKI潜在治疗RF的成分;同时基于网络药理学预测SKI调控RF的核心靶点及通路;最后,通过分子对接和细胞实验进行验证。结果 基于GEO数据库筛选到2个RF相关的数据集,CMAP重定位到3个共同的RF治疗药物(saracatinib、dasatinib、PP-2),分子指纹相似性分析发现,RF治疗药物与salvianolic acid B、hydroxysafflor yellow A等5个SKI成分的结构相似性较高。分子对接结果发现,salvianolic acid B、hydroxysafflor yellow A等成分与SKI调控的潜在治疗RF的核心靶标MMP1、MMP13等均有良好的结合能力。网络药理学分析提示,SKI核心靶点主要富集在Relaxin和AGE-RAGE等信号通路。细胞实验表明,SKI可显著降低RF模型细胞AGE-RAGE信号通路中AGER、NFKB1、COL1A1、SERPINE1、VEGFC和Relaxin信号通路中MMP1、MMP13的mRNA表达水平,显著升高RXFP1的mRNA表达水平。结论 SKI可通过调控Relaxin和AGE-RAGE信号通路来发挥治疗RF的作用,其物质基础可能为salvianolic acid B、hydroxysafflor yellow A等成分。 展开更多
关键词 肾康注射液 肾纤维化 生物信息学 药物重定位 实验验证 作用机制
下载PDF
基于申康医联平台的急性胰腺炎专病数据库设计与应用
7
作者 吴晓萍 郑涛 +3 位作者 陈朝飞 陈珊黎 邵维君 丁粉华 《计算机应用与软件》 北大核心 2024年第5期9-14,39,共7页
为了更好地满足急性胰腺炎临床科研需求,迫切需建立标准统一、多中心专病数据库,指导临床持续改进诊疗质量。在市政府的支持下,联合9家市级医院合作制定多中心急性胰腺炎标准数据模型。基于申康医联平台,将多中心多源异构数据融合自然... 为了更好地满足急性胰腺炎临床科研需求,迫切需建立标准统一、多中心专病数据库,指导临床持续改进诊疗质量。在市政府的支持下,联合9家市级医院合作制定多中心急性胰腺炎标准数据模型。基于申康医联平台,将多中心多源异构数据融合自然语言处理技术标准化,深度处理整合。实现结构化专病数据库,已支持科研人员开展相关临床研究。市级急性胰腺炎专病数据库可促进数据汇聚标准化,提高临床科研水平,同时促进信息化的应用。 展开更多
关键词 急性胰腺炎 申康医联平台 自然语言处理 多中心合作
下载PDF
Preventive effect of Shenkang injection against high glucose-induced senescence of renal tubular cells 被引量:10
8
作者 Biqiong Fu Jie Yang +5 位作者 Jia Chen Lirong Lin Kehong Chen Weiwei Zhang Jianguo Zhang Yani He 《Frontiers of Medicine》 SCIE CAS CSCD 2019年第2期267-276,共10页
Shenkang injection (SKI) is a classic prescription composed of Radix Astragali, rhubarb, Astragalus, Safflower, and Salvia. This treatment was approved by the State Food and Drug Administration of China in 1999 for tr... Shenkang injection (SKI) is a classic prescription composed of Radix Astragali, rhubarb, Astragalus, Safflower, and Salvia. This treatment was approved by the State Food and Drug Administration of China in 1999 for treatment of chronic kidney diseases based on good efficacy and safety. This study aimed to investigate the protective effect of SKI against high glucose (HG)-induced renal tubular cell senescence and its underlying mechanism. Primary renal proximal tubule epithelial cells were cultured in (1) control medium (control group), medium containing 5 mmol/L glucose;(2) mannitol medium (mannitol group), medium containing 5 mmol/L glucose, and 25 mmol/L mannitol;(3) HG medium (HG group) containing 30 mmol/L glucose;(4) SKI treatment at high (200 mg/L), medium (100 mg/L), or low (50 mg/L) concentration in HG medium (HG+ SKI group);or (5) 200 mg/L SKI treatment in control medium (control+ SKI group) for 72 h. HG-induced senescent cells showed the emergence of senescence associated heterochromatin foci, up-regulation of P16INK4 and cyclin D1, increased senescence-associated β-galactosidase activity, and elevated expression of membrane decoy receptor 2. SKI treatment potently prevented these changes in a dose-independent manner. SKI treatment prevented HG-induced up-regulation of pro-senescence molecule mammalian target of rapamycin and p66Shc and down-regulation of anti-senescence molecules klotho, sirt1, and peroxisome proliferator-activated receptor-g in renal tubular epithelial cells. SKI may be a novel strategy for protecting against HG-induced renal tubular cell senescence in treatment of diabetic nephropathy. 展开更多
关键词 shenkang injection SENESCENCE RENAL tubular EPITHELIAL cells DIABETIC NEPHROPATHY
原文传递
Shenkang injection improves coagulation in patients with chronic kidney disease: a systematic review and Meta-analysis 被引量:3
9
作者 Song Zilin Qin Tianyu +3 位作者 Pan Yajing Hua Qian Wu Lili Liu Tonghua 《Journal of Traditional Chinese Medicine》 SCIE CAS CSCD 2019年第4期451-458,共8页
OBJECTIVE: To investigate the effect of Shenkang injection(SKI) on chronic kidney disease(CKD).METHODS: Seven databases including Cochrane Central Register of Controlled Trials, PubMed, EMBASE, MEDLINE, China National... OBJECTIVE: To investigate the effect of Shenkang injection(SKI) on chronic kidney disease(CKD).METHODS: Seven databases including Cochrane Central Register of Controlled Trials, PubMed, EMBASE, MEDLINE, China National Knowledge Infrastructure, Wanfang Database, and CQVIP from their inception to March 2018 were searched. Only randomized controlled trials that evaluated conventional treatment and conventional treatment with SKI in CKD patients were investigated. Outcomes such as fibrinogen(FIB), D-dimer, prothrombin time(PT), activated partial thromboplastin time(APTT), and the side effects of SKI were analyzed using Revman 5.3 software. The quality of the studies was assessed using the Cochrane Collaboration’s Risk of Bias tool and the quality of evidence was assessed using GRADEpro.RESULTS: Four randomized controlled trials were investigated in our analysis, and these studies were of moderate quality. For FIB and D-dimer, SKI had a superior effect compared with the control group(mean difference(MD)=-1.23, 95% confidence interval(CI):-1.46,-0.99, P < 0.01;MD =-0.36, 95%CI:-0.51,-0.21, P < 0.01, respectively)SKI increased APTT and PT compared with the control(MD = 7.34, 95% CI: 3.05, 11.62, P < 0.01;MD = 3.40,95% CI: 2.2, 4.61, P < 0.01, respectively). In the four studies, there were no side effects that were related to SKI.CONCLUSION: SKI may be effective in improving coagulation in patients with CKD without obvious adverse reactions. However, more well-designed studies are required to confirm the findings. 展开更多
关键词 RENAL insufficiency chronic Coagulates shenkang injection Review META-ANALYSIS
原文传递
Shenkang Injection protects against diabetic nephropathy in streptozotocin(STZ)-induced mice through enhancement of anti-oxidant and anti-inflammatory activities 被引量:3
10
作者 Bin Zhang Xue-lian Zhang +2 位作者 Chen-yang Zhang Gui-bo Sun Xiao-bo Sun 《Chinese Herbal Medicines》 CAS 2020年第3期289-296,共8页
Objective:To investigate the protective effects and possible mechanisms of Shenkang Injection(SKI)on the diabetic nephropathy in streptozotocin-induced mice.Methods:STZ with the feeding of high fat diet(HFD)was used t... Objective:To investigate the protective effects and possible mechanisms of Shenkang Injection(SKI)on the diabetic nephropathy in streptozotocin-induced mice.Methods:STZ with the feeding of high fat diet(HFD)was used to induce diabetic mice.The balb/c mice and diabetic mice were then randomly divided into five groups:(1)control group,(2)model group,(3)alprostadil(Alp,1.5μg/kg)group,(4)SKI(30 ml/kg)group,(5)Alp(1.5μg/kg)+SKI(15 ml/kg)group.After six weeks'treatment,blood,urine and kidney tissues were collected for biochemical assay,EUSA assay,and pathological analysis.Results:Diabetic mice exhibited evident manifestations of diabetic nephropathy(DN),as indicated by increased 24-h urine volume,urinary albumin and kidney weight index(P<0.01),which could be attenuated by SKI treatment(P<0.01).SKI was further found to improve abnormal morphology in glomerulus with increased glomerular volume and to decrease urinary N-acetyl-b-D-glucpsaminidase(NAG),β2-microglobulin(β2-MG),and kidney injury molecules-1(KIM-1)levels(P<0.05,P<0.01).Plasma levels of anti-oxidant enzymes significantly reduced in the diabetic mice,and those decreases could be reversed by SKI and Alp treatments.Additionally,SKI obviously suppressed the diabetes-induced increases of proinflammatory cytokines(IL-6,IL-1βand TNF-α)(P<0.01).Meanwhile,SKI was found to effectively attenuate the diabetes-induced coagulation dysfunction,as evidenced by lengthening prothrombin and thrombin time,and decreasing plasma levels of fibrinogen(FIB),6-K-PGF1αand thromboxane B2(TXB2)(P<0.05,P<0.01).With SKI and Alp combined treatment,the anti-oxidant activities and improvements of coagulation dysfunction were enhanced.Conclusion:SKI possesses a remarkable property to prevent diabetic nephropathy.The improvements of kidney function and hypercoagulability by SKI were enhanced with Alp combined treatment.The molecular mechanisms underlying the protection of SKI against DN may be related to enhancing the antioxidant and anti-inflammatory activities,and improving the coagulation dysfunction. 展开更多
关键词 shenkang Injection diabetic nephropathy INFLAMMATION oxidative stress
原文传递
肾康注射液联合中药结肠透析治疗慢性肾脏病的临床效果分析
11
作者 陈玲 贺新立 +1 位作者 孙尚萍 齐广瑞 《中国社区医师》 2024年第19期85-87,共3页
目的:分析肾康注射液联合中药结肠透析治疗慢性肾脏病的临床效果。方法:选取2022年1月—2024年2月遵义市中医院收治的慢性肾脏病患者80例作为研究对象,采用随机数字表法分为试验组和对照组,各40例。对照组采取中药结肠透析治疗,试验组... 目的:分析肾康注射液联合中药结肠透析治疗慢性肾脏病的临床效果。方法:选取2022年1月—2024年2月遵义市中医院收治的慢性肾脏病患者80例作为研究对象,采用随机数字表法分为试验组和对照组,各40例。对照组采取中药结肠透析治疗,试验组在对照组基础上采取肾康注射液治疗。对比两组患者治疗效果。结果:治疗后,两组尿素氮、血肌酐、血尿酸、血清胱抑素C、尿蛋白、超敏C反应蛋白水平均低于治疗前,且试验组低于对照组,差异有统计学意义(P<0.05)。试验组治疗总有效率高于对照组(P=0.004)。两组不良反应发生率对比,差异无统计学意义(P>0.05)。结论:肾康注射液联合中药结肠透析治疗慢性肾脏病的临床效果良好,能够促进患者肾功能改善、炎性指标降低,且治疗安全性较高。 展开更多
关键词 肾康注射液 中医结肠透析 慢性肾脏病
下载PDF
免疫抑制剂联用中成药对难治性肾病综合征肾功能、血脂水平的影响
12
作者 倪斌 高畅 郭春钰 《药品评价》 CAS 2024年第5期630-633,共4页
目的探讨免疫抑制剂联用中成药对难治性肾病综合征(RNS)肾功能、血脂水平的影响。方法回顾性分析2019年1月至2023年6月赣南医科大学第一附属医院收治的118名RNS患者病例,根据治疗方案不同,分为环磷酰胺组(A组)、环磷酰胺+肾康栓组(B组)... 目的探讨免疫抑制剂联用中成药对难治性肾病综合征(RNS)肾功能、血脂水平的影响。方法回顾性分析2019年1月至2023年6月赣南医科大学第一附属医院收治的118名RNS患者病例,根据治疗方案不同,分为环磷酰胺组(A组)、环磷酰胺+肾康栓组(B组)、环磷酰胺+黄葵胶囊组(C组)、环孢素组(D组)、环孢素+肾康栓组(E组)及环孢素+黄葵胶囊组(F组)。依据肾功能、血脂水平及药品不良反应作为评价指标,分别对环磷酰胺、环孢素联用中成药的肾功能、血脂水平变化进行分析。结果治疗后,各组24 h尿蛋白定量(24 h-UTP)、人血白蛋白(ALB)、血清肌酐(CRE)、血尿素氮(UREA)、总胆固醇(TC)、甘油三脂(TG)、低密度脂蛋白胆固醇(LDL-C)均显著改善(P<0.05)。C组较于A组24 h-UTP下降,差异有统计学意义(P<0.05);E组较于D组TC下降差异有统计学意义(P<0.05);F组较于D组24 h-UTP、TC下降,差异有统计学意义(P<0.05)。结论免疫抑制剂环磷酰胺、环孢素能够有效治疗RNS的患者,联用黄葵胶囊降低蛋白尿排泄及高脂水平;联用肾康栓改善高脂水平。 展开更多
关键词 难治性肾病综合征 环磷酰胺 环孢素 肾康栓 黄葵胶囊
下载PDF
肾康注射液用于糖尿病肾病治疗的快速卫生技术评估
13
作者 刘琳 刘娜 +1 位作者 马超群 窦琬婷 《糖尿病新世界》 2024年第1期190-194,共5页
目的 快速卫生技术评估肾康注射液用于糖尿病肾病治疗的有效性、安全性及经济性,为临床实践和决策者提供循证依据。方法 检索PubMed、Cochrane Library、Embase和CNKI、VIP、WanFang、SinoMed等数据库以及卫生技术评估(Health Technolog... 目的 快速卫生技术评估肾康注射液用于糖尿病肾病治疗的有效性、安全性及经济性,为临床实践和决策者提供循证依据。方法 检索PubMed、Cochrane Library、Embase和CNKI、VIP、WanFang、SinoMed等数据库以及卫生技术评估(Health Technology Assessment, HTA)网站,设置检索文献发表时间为2000年1月1日—2023年5月31日,对肾康注射液用于糖尿病肾病治疗的相关循证证据进行汇总分析。结果 共纳入8篇文献,结果显示,与常规治疗相比,肾康注射液在尿素氮(Blood Urea Nitrogen, BUN)、血肌酐(Serum Creatinine,SCr)、尿白蛋白排泄率(Urinary Albumin Excretion Rates, UAER)和总有效率等方面均有明显改善,差异有统计学意义(P均<0.05)。肾康注射液总体安全性较好,其不良反应以注射部位疼痛、潮红为主,但经济性方面不占优势。结论 肾康注射液用于糖尿病肾病的治疗有较好的有效性、安全性,但其经济性不占优势。 展开更多
关键词 肾康注射液 糖尿病肾病 循证评价
下载PDF
肾康注射液联合百令片治疗老年糖尿病肾病患者的效果
14
作者 卜巧云 《中国民康医学》 2024年第12期120-123,共4页
目的:观察肾康注射液联合百令片治疗老年糖尿病肾病(DN)患者的效果。方法:回顾性分析2021年8月至2023年5月该院收治的68例老年DN患者的临床资料,按照治疗方法不同将其分为对照组和观察组各34例。两组均予以对症治疗,在此基础上,对照组... 目的:观察肾康注射液联合百令片治疗老年糖尿病肾病(DN)患者的效果。方法:回顾性分析2021年8月至2023年5月该院收治的68例老年DN患者的临床资料,按照治疗方法不同将其分为对照组和观察组各34例。两组均予以对症治疗,在此基础上,对照组予以百令片治疗,观察组在对照组基础上联合肾康注射液治疗,两组均治疗4周。比较两组临床疗效,治疗前后肾功能指标[24 h尿蛋白定量(24hUP)、血肌酐(Scr)、血尿素氮(BUN)]水平、凝血功能指标[纤维蛋白原(FIB)、凝血酶原时间(PT)]水平、氧化应激指标[超氧化物歧化酶(SOD)、丙二醛(MDA)]水平、转化生长因子-β1(TGF-β1)水平,以及不良反应发生率。结果:观察组治疗总有效率为94.12%(32/34),高于对照组的76.47%(26/34),差异有统计学意义(P<0.05);治疗后,观察组24hUP、Scr、BUN水平均低于对照组,差异有统计学意义(P<0.05);治疗后,观察组PT长于对照组,FIB水平低于对照组,差异均有统计学意义(P<0.05);治疗后,观察组SOD水平高于对照组,MDA、TGF-β1水平低于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:肾康注射液联合百令片治疗老年DN患者可提高治疗总有效率,降低肾功能指标水平,改善凝血功能指标和氧化应激指标水平,降低TGF-β1水平,效果优于单纯百令片治疗。 展开更多
关键词 老年 糖尿病肾病 肾康注射液 百令片 氧化应激 肾功能 转化生长因子-Β1
下载PDF
肾康注射液联合连续性肾脏替代治疗脓毒症合并急性肾损伤患者的效果
15
作者 齐江燕 《中国民康医学》 2024年第1期92-95,共4页
目的:观察肾康注射液联合连续性肾脏替代治疗(CRRT)脓毒症合并急性肾损伤(AKI)患者的效果。方法:回顾性分析2021年2月至2023年2月该院收治的106例脓毒症合并AKI患者的临床资料,根据治疗方案不同将其分为对照组与研究组各53例。对照组行C... 目的:观察肾康注射液联合连续性肾脏替代治疗(CRRT)脓毒症合并急性肾损伤(AKI)患者的效果。方法:回顾性分析2021年2月至2023年2月该院收治的106例脓毒症合并AKI患者的临床资料,根据治疗方案不同将其分为对照组与研究组各53例。对照组行CRRT治疗,研究组在对照组基础上联合肾康注射液治疗,比较两组临床疗效、治疗前后中医证候积分、器官功能损伤程度[序贯性器官功能衰竭(SOFA)]评分、肾功能指标[胱抑素C(CysC)、血肌酐(Scr)、β_(2)-微球蛋白(β_(2)-MG)、血尿素氮(BUN)]水平、炎性指标[肾损伤分子-1(KIM-1)、可溶性细胞间黏附分子-1(sICAM-1)、C反应蛋白(CRP)、中性粒细胞明胶酶相关载脂蛋白(NGAL)]水平,以及不良反应发生率。结果:研究组治疗总有效率为94.34%(50/53),高于对照组的81.13%(43/53),差异有统计学意义(P<0.05);治疗后,两组中医证候积分、SOFA评分均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组CysC、Scr、β_(2)-MG、BUN水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组KIM-1、sICAM-1、CRP、NGAL水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);研究组不良反应发生率为3.76%,低于对照组的15.04%,差异有统计学意义(P<0.05)。结论:肾康注射液联合CRRT治疗脓毒症合并AKI患者可提高治疗总有效率,降低中医证候积分、SOFA评分、肾功能指标水平、炎性指标水平和不良反应发生率,其效果优于单纯CRRT治疗。 展开更多
关键词 脓毒症 急性肾损伤 肾康注射液 连续性血液透析 中医证候积分 炎性因子 肾功能
下载PDF
肾康注射液联合非布司他治疗痛风性肾病合并慢性肾衰竭患者的效果
16
作者 朱方丽 沈浩 董磊鹏 《中国民康医学》 2024年第4期110-113,共4页
目的:观察肾康注射液联合非布司他治疗痛风性肾病(GN)合并慢性肾衰竭(CRF)患者的效果。方法:回顾性分析2021年5月至2023年5月该院收治的134例GN合并CRF患者的临床资料,按照治疗方法不同将其分为对照组和观察组各67例。对照组采用非布司... 目的:观察肾康注射液联合非布司他治疗痛风性肾病(GN)合并慢性肾衰竭(CRF)患者的效果。方法:回顾性分析2021年5月至2023年5月该院收治的134例GN合并CRF患者的临床资料,按照治疗方法不同将其分为对照组和观察组各67例。对照组采用非布司他治疗,观察组在对照组基础上联合肾康注射液治疗,比较两组临床疗效,治疗前后肾功能指标[估算肾小球滤过率(eGFR)、血肌酐(Scr)、血尿素氮(BUN)]水平、氧化应激指标[超氧化物歧化酶(SOD)、髓过氧化物酶(MPO)、丙二醛(MDA)]水平、肾纤维化指标[成纤维细胞生长因子2(FGF2)、骨形态发生蛋白-7(BMP-7)、结缔组织生长因子(CTGF)]水平,以及不良反应发生率。结果:观察组治疗总有效率为91.04%(61/67),高于对照组的77.61%(52/67),差异有统计学意义(P<0.05);治疗后,观察组eGFR、SOD、BMP-7水平均高于对照组,Scr、BUN、MPO、MDA、FGF2、CTGF水平均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:肾康注射液联合非布司他治疗GN合并CRF患者可提高治疗总有效率,改善肾功能指标、氧化应激指标和肾纤维化指标水平,效果优于单纯非布司他治疗。 展开更多
关键词 痛风性肾病 慢性肾衰竭 肾康注射液 非布司他 肾功能 肾纤维化 氧化应激
下载PDF
肾康注射液联合前列地尔注射液治疗慢性肾衰竭患者的效果
17
作者 朱佳佳 吴茜彤 焦亚彬 《中国民康医学》 2024年第19期106-109,共4页
目的:观察肾康注射液联合前列地尔注射液治疗慢性肾衰竭患者的效果。方法:选取2020年8月至2023年8月该院收治的156例慢性肾衰竭患者进行前瞻性研究,按照随机数字表法将其分为研究组和对照组各78例。两组均予以常规治疗,在此基础上,对照... 目的:观察肾康注射液联合前列地尔注射液治疗慢性肾衰竭患者的效果。方法:选取2020年8月至2023年8月该院收治的156例慢性肾衰竭患者进行前瞻性研究,按照随机数字表法将其分为研究组和对照组各78例。两组均予以常规治疗,在此基础上,对照组予以前列地尔注射液治疗,研究组在对照组基础上联合肾康注射液治疗,两组均治疗28 d。比较两组临床疗效,治疗前后炎性因子[肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)]、肾功能指标[血肌酐(Scr)、血尿素氮(BUN)、24 h尿蛋白定量(24hUP)]、肾纤维化指标[Ⅳ型胶原蛋白(Ⅳ-C)、层粘连蛋白(LN)、透明质酸(HA)、转化生长因子-β1(TGF-β1)]水平,以及不良反应发生率。结果:研究组治疗总有效率为93.59%(73/78),高于对照组的83.33%(65/78),差异有统计学意义(P<0.05);治疗后,研究组TNF-α、IL-1β、IL-6水平均低于对照组,差异有统计学意义(P<0.05);治疗后,研究组Scr、BUN、24hUP水平均低于对照组,差异有统计学意义(P<0.05);治疗后,研究组Ⅳ-C、LN、HA、TGF-β1水平均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:肾康注射液联合前列地尔注射液治疗慢性肾衰竭患者可提高治疗总有效率,降低炎性因子、肾功能指标、肾纤维化指标水平,效果优于单纯前列地尔注射液治疗。 展开更多
关键词 前列地尔注射液 肾康注射液 慢性肾衰竭 肾功能 炎性因子 肾纤维化 不良反应
下载PDF
肾康注射液联合西药治疗肾病综合征疗效的Meta分析 被引量:2
18
作者 张丽 郭静 +5 位作者 李春晓 杨玉晴 张佳楠 杨亚蕾 凌霄 王盼盼 《世界中西医结合杂志》 2023年第7期1302-1309,1318,共9页
目的系统评价肾康注射液联合西药治疗肾病综合征的临床疗效及安全性。方法检索中国知网、万方数据库、维普中文数据库、中国生物医学文献服务系统、Web of Science、Embase、PubMed及Cochrane Library数据库自建库至2022年6月30日期间... 目的系统评价肾康注射液联合西药治疗肾病综合征的临床疗效及安全性。方法检索中国知网、万方数据库、维普中文数据库、中国生物医学文献服务系统、Web of Science、Embase、PubMed及Cochrane Library数据库自建库至2022年6月30日期间所有肾康注射液联合西药治疗肾病综合征(Nephrotic syndrome,NS)的随机对照试验(Randomized controlled trial,RCT),并由两名研究人员提取资料并进行质量评价,采用Review Manager 5.4.1软件和R语言进行Meta分析。结果共纳入19篇文献,涉及1509例患者,治疗组763例,对照组746例。Meta分析结果显示:肾康注射液联合西药较单纯西药治疗肾病综合征可以显著提高临床总有效率[RR=1.27,95%CI(1.20;1.34),P<0.00001]、内生肌酐清除率(Creatinine clearance rate,Ccr)[MD=6.36,95%CI(3.04;9.68),P=0.0002]、血浆白蛋白(Plasma Albumin,ALB)[MD=4.94,95%CI(3.23;6.64),P<0.00001]水平,能有效降低甘油三酯(Triglycerides,TG)[MD=-0.86,95%CI(-1.05;-0.67),P<0.00001]、总胆固醇(Total cholesterol,TC)[MD=-1.44,95%CI(-2.14;-0.74),P<0.00001]、血清肌酐(Serum creatinine,Scr)[MD=-33.60,95%CI(-67.03;-0.17),P<0.00001]、尿素氮(Urea nitrogen,BUN)[MD=-2.47,95%CI(-2.89;-2.05),P<0.00001]、24 h尿蛋白定量(24 h urine total protein,24 h UTP)[MD=-0.57,95%CI(-0.78;-0.35),P<0.00001]水平,且差异有统计学意义。结论肾康注射液联合西药可以提高肾病综合征患者的临床总有效率,提高Ccr和ALB,能有效降低TG、低胆固醇、Scr、BUN和24 h UTP,在一定程度上可以减少肾病综合征患者的肾功能的损伤。 展开更多
关键词 肾康注射液 肾病综合征 META分析
下载PDF
中药结肠透析联合肾康注射液治疗慢性肾脏病3~4期临床观察 被引量:1
19
作者 王吉磊 刘世宾 +1 位作者 宿晶 房婧 《中国中医药现代远程教育》 2023年第2期145-147,共3页
目的观察中药结肠透析联合肾康注射液对慢性肾脏病(CKD)3~4期患者的临床疗效。方法60例确诊患者随机分为对照组(肾康注射液治疗)30例和观察组(肾康注射液联合中药结肠透析治疗)30例,观察用药前后2组患者血尿素氮(BUN)、肌酐(Scr)、尿酸(... 目的观察中药结肠透析联合肾康注射液对慢性肾脏病(CKD)3~4期患者的临床疗效。方法60例确诊患者随机分为对照组(肾康注射液治疗)30例和观察组(肾康注射液联合中药结肠透析治疗)30例,观察用药前后2组患者血尿素氮(BUN)、肌酐(Scr)、尿酸(UA)、血清胱抑素C(Cys-C)、超敏C反应蛋白(hs-CRP)的变化。结果治疗后,2组患者的BUN、Scr、UA、Cys-C、hs-CRP水平均有改善,差异有统计学意义(P<0.05),并且观察组优于对照组(P<0.05)。结论中药结肠透析联合肾康注射液可明显改善慢性肾脏病3~4期患者肾功能、降低炎症因子水平,延缓肾功能进展,并且安全性好。 展开更多
关键词 中药结肠透析 肾康注射液 慢性肾脏病3~4期 中西医结合疗法
下载PDF
肾康注射液联合穴位敷贴治疗慢性肾功能衰竭疗效及作用机制 被引量:6
20
作者 王艳芬 马琴 王顺 《陕西中医》 CAS 2023年第5期595-599,共5页
目的:探讨肾康注射液联合穴位敷贴治疗慢性肾功能衰竭(CRF)的临床疗效及作用机制。方法:选取150例CRF患者,依据随机数字表法分为两组,各75例。对照组予肾康注射液治疗,治疗组予肾康注射液联合穴位敷贴治疗。比较两组总有效率、治疗前后... 目的:探讨肾康注射液联合穴位敷贴治疗慢性肾功能衰竭(CRF)的临床疗效及作用机制。方法:选取150例CRF患者,依据随机数字表法分为两组,各75例。对照组予肾康注射液治疗,治疗组予肾康注射液联合穴位敷贴治疗。比较两组总有效率、治疗前后症状体征积分、肾功能、氧化应激和肾纤维化指标。结果:治疗组总有效率92.00%高于对照组的74.67%(P<0.05)。治疗后两组症状体征有所缓解,且治疗组恶心呕吐、腰膝酸软、倦怠乏力、脘腹胀满、口渴不饮、食欲欠佳积分均低于对照组(P<0.05)。治疗后两组血肌酐(Scr)、血尿素氮(BUN)、血尿酸(UA)、活性氧(ROS)、丙二醛(MDA)、透明质酸(HA)、Ⅲ型前胶原(PCⅢ)、半胱氨酸蛋白酶抑制蛋白C(Cys-C)均较治疗前降低,内生肌酐清除率(Ccr)、超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)较治疗前升高,且治疗组上述指标优于对照组(P<0.05)。治疗组总不良反应发生率为6.67%,与对照组的14.67%比较差异无统计学意义(P>0.05)。结论:肾康注射液联合穴位敷贴治疗CRF疗效显著,可明显缓解患者临床症状,改善肾功能,其机制可能与该方能有效调节氧化应激、抑制肾纤维化进展有关。 展开更多
关键词 慢性肾衰竭 肾功能衰竭期 肾康注射液 穴位敷贴 肾功能 氧化应激
下载PDF
上一页 1 2 22 下一页 到第
使用帮助 返回顶部